[go: up one dir, main page]

WO2002064796A8 - Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use - Google Patents

Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use

Info

Publication number
WO2002064796A8
WO2002064796A8 PCT/US2001/050450 US0150450W WO02064796A8 WO 2002064796 A8 WO2002064796 A8 WO 2002064796A8 US 0150450 W US0150450 W US 0150450W WO 02064796 A8 WO02064796 A8 WO 02064796A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
butyrylcholinesterase
polypeptide variants
catalytic efficiency
increased catalytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/050450
Other languages
French (fr)
Other versions
WO2002064796A2 (en
WO2002064796A3 (en
Inventor
Oksana Lockridge
Jeffry D Watkins
James D Pancook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nebraska Medical Center UNMC
Applied Molecular Evolution Inc
Original Assignee
University of Nebraska Medical Center UNMC
Applied Molecular Evolution Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/748,739 external-priority patent/US7070973B2/en
Priority claimed from US10/032,233 external-priority patent/US20030153062A1/en
Application filed by University of Nebraska Medical Center UNMC, Applied Molecular Evolution Inc filed Critical University of Nebraska Medical Center UNMC
Priority to EP01997137A priority Critical patent/EP1414974A2/en
Priority to CA002433057A priority patent/CA2433057A1/en
Priority to AU2002248256A priority patent/AU2002248256B2/en
Priority to JP2002565109A priority patent/JP4252311B2/en
Publication of WO2002064796A2 publication Critical patent/WO2002064796A2/en
Anticipated expiration legal-status Critical
Publication of WO2002064796A8 publication Critical patent/WO2002064796A8/en
Publication of WO2002064796A3 publication Critical patent/WO2002064796A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C12Q1/46—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase involving cholinesterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01008—Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides twenty-five butyrylcholinesterase variants having increased cocaine hydrolysis activity as well as the corresponding encoding nucleic acids. The invention also provides libraries of butyrylcholinesterase variants as well as libraries of the corresponding nucleic acids encoding butyrylcholinesterase variants. The invention further provides methods of hydrolyzing a cocaine-based butyrylcholinesterase substrate as well as methods of treating a cocaine-induced condition.
PCT/US2001/050450 2000-12-26 2001-12-21 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use Ceased WO2002064796A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01997137A EP1414974A2 (en) 2000-12-26 2001-12-21 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
CA002433057A CA2433057A1 (en) 2000-12-26 2001-12-21 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
AU2002248256A AU2002248256B2 (en) 2000-12-26 2001-12-21 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
JP2002565109A JP4252311B2 (en) 2000-12-26 2001-12-21 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/748,739 2000-12-26
US09/748,739 US7070973B2 (en) 2000-12-26 2000-12-26 Butyrylcholinesterase variants and methods of use
US10/032,233 2001-12-20
US10/032,233 US20030153062A1 (en) 2001-12-20 2001-12-20 Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use

Publications (3)

Publication Number Publication Date
WO2002064796A2 WO2002064796A2 (en) 2002-08-22
WO2002064796A8 true WO2002064796A8 (en) 2003-11-13
WO2002064796A3 WO2002064796A3 (en) 2003-12-31

Family

ID=26708157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050450 Ceased WO2002064796A2 (en) 2000-12-26 2001-12-21 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use

Country Status (5)

Country Link
EP (1) EP1414974A2 (en)
JP (1) JP4252311B2 (en)
AU (1) AU2002248256B2 (en)
CA (1) CA2433057A1 (en)
WO (1) WO2002064796A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142875A (en) * 2001-04-30 2009-08-03 Avigdor Shafferman Cholinesterases conjugated to peg for scavenging organophosphates in circulation
JP4781628B2 (en) * 2001-12-05 2011-09-28 センス プロテオミック リミテッド Protein arrays for allelic variants and uses thereof
US6989261B2 (en) * 2001-12-20 2006-01-24 Eli Lilly And Company Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
GB0202018D0 (en) 2002-01-29 2002-03-13 Sense Proteomic Ltd Tag and method
EP1581253A4 (en) * 2002-12-04 2007-02-14 Applied Molecular Evolution Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
CN101500600A (en) * 2006-06-07 2009-08-05 人类生物分子研究所 Methods for ester detoxication
EP3137098A4 (en) * 2014-04-29 2017-11-01 Mayo Foundation for Medical Education and Research Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin
WO2018053216A1 (en) 2016-09-15 2018-03-22 Mayo Foundation For Medical Education And Research Methods and materials for using butyrylcholinesterases to treat cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001625A (en) * 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases

Also Published As

Publication number Publication date
AU2002248256B2 (en) 2006-09-28
CA2433057A1 (en) 2002-08-22
WO2002064796A2 (en) 2002-08-22
JP2004535155A (en) 2004-11-25
WO2002064796A3 (en) 2003-12-31
JP4252311B2 (en) 2009-04-08
EP1414974A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
AU7957898A (en) Nucleic acids encoding polypeptide having protease activity
CA2268043A1 (en) Improvements in or relating to starch content of plants
WO2001079464A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
WO2001079463A3 (en) Nucleic acids encoding polypeptides having haloperoxidase activity
AU2001241674A1 (en) Variant galactose oxidase, nucleic acid encoding same, and methods of using same
WO2004092340A3 (en) Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
WO2002064796A3 (en) Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
AU1103300A (en) Zinc finger peptide cleavage of nucleic acids
EP1329153A4 (en) Plant having improved tolerance to various environmental stresses, method of constructing the same and polyamine metabolism-relating enzyme gene
AU2002312627A1 (en) Nucleic acids encoding glucosinolate biosynthesis enzymes and methods of their use
AU2001269039A1 (en) Immobilized nucleic acids and uses thereof
AU1747797A (en) Nucleic acids encoding polypeptides having absidia lipase activity
AU7677298A (en) Enantioselective epoxide hydrolases and genes encoding these
WO2002092841A3 (en) Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
WO2002072786A3 (en) Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
EP1757684A3 (en) A 2,6-beta-D-fructan hydrolase enzyme and processes for using the enzyme
WO2001059102A3 (en) Nucleozymes with endonuclease activity
AU2002239529A1 (en) Prostate-specific polypeptide pamp and encoding nucleic acid molecules
AU2002239570A1 (en) Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
AU7846000A (en) Novel human lipase proteins, nucleic acids encoding them, and uses of both of these
WO2002090531A3 (en) Peptidylarginine deiminase 6
ITTO981057A0 (en) CLEANING METHOD WITH MIXTURE OF HYDROCHLORIC ACID AND HYDROGEN PEROXIDE.
AU2001238407A1 (en) Esterase enzymes having selective activity
WO1999035271A3 (en) Vibrio cholerae vaccine candidates and method of their constructing
AU2002368222A1 (en) Esterases, nucleic acids encoding them and methods of making and using them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2433057

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002565109

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002248256

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001997137

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 34/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

Free format text: IN PCT GAZETTE 34/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.

WWP Wipo information: published in national office

Ref document number: 2001997137

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002248256

Country of ref document: AU